2
2
2
2
3
3
2
2
2008
2005
Company (9)University (2)
1 - 9 of 9
Sort by
Patent
Publication NumberUS 7470787Filing StatusIssued PatentAvailabilityUnknownFiling Date2006-07-11Publication Date2008-12-30
Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
Patent
Publication NumberUS 7332292Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-02-26Publication Date2008-02-19
The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a GPCR is expressed at the plasma membrane, and if the GPCR has an affinity for arrestin. Modified GPCRs which have increased arrestin affinity are included in the pres…
Patent
Publication NumberUS 7297503Filing StatusIssued PatentAvailabilityUnknownFiling Date2003-10-24Publication Date2007-11-20
Described herein are methods of identifying a transmembrane receptor (TMR) agonist and compounds identified by this method. The TMR agonist (TMRA) is capable of activating TMR signaling while exhibiting reduced TMR internalization over a control compound.
Patent
Publication NumberUS 20070196865Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2004-09-16Publication Date2007-08-23
Methods of screening compositions for G protein-coupled receptor (“GPCR”) agonist activity against two or more GPCRs in a multiplex receptor assay format are disclosed. One or more cells expressing at least two different GPCRs are exposed to a test composition and it is determined whether or not the composition gives an indication of GPCR agonist activity with respect to any of the at least two different GPCRs. Each of the one or more cells also includes one or more conjugates comprising a ma…
Patent
Publication NumberUS 7163800Filing StatusIssued PatentAvailabilityUnknownFiling Date2003-08-01Publication Date2007-01-16
The methods of the present invention allow the screening of a test composition for non-receptor-specific GPCR desensitization inhibitory activity. The methods involve screening a test composition for an indication of GPCR desensitization inhibitory activity against two or more GPCRs that are different from each other. When there is an indication that a particular test composition has GPCR desensitization inhibitory activity with respect to each of the two or more GPCRs that are different from…
SEC Filing
Accession Number9999999997-06-033903Form TypeREGDEXAcceptance Date2006-08-08
This document was generated as part of a paper submission.Please reference the Document Control Number 06044038 for access to the original document.
Patent
Publication NumberUS 20060029983Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2005-01-21Publication Date2006-02-09
The present invention relates to methods of treating disease by altering G protein coupled receptor kinase (GRK) 6. This may be done by altering the expression or activity of the protein, for example. The present invention may be used for disease diagnosis, by detecting the expression or activity of GRK6. The present invention relates to a GRK6 deficient mouse, GRK6 splice variants, and methods of use. The present invention also relates to methods of identifying compounds that alter GRK6 acti…
Clinical Trial
Clinical Trial IDNCT00298636Start Date2005-10-01PhasePhase 2Study TypeInterventionalStatusCompleted
Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. Activated spinal A1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential, which is the C-fiber-evoked excitatory response associated with nociception. Adenosine may inhibit intrinsic neurons through an increase in K+ conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance P and per…
Patent
Publication NumberUS 20050136431Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2004-07-29Publication Date2005-06-23
The methods of the present invention allow the screening of a test composition for non-receptor-specific GPCR desensitization inhibitory activity. The methods involve screening a test composition for an indication of GPCR desensitization inhibitory activity against two or more GPCRs that are different from each other. When there is an indication that a particular test composition has GPCR desensitization inhibitory activity with respect to each of the two or more GPCRs that are different from…
We found 9 documents that match your Search
Patents: 7
Clinical Trials: 1
SEC Filings: 1

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in